Safety and Efficacy of Xalkori ROS1

XALKORI ROS1+NSCLC DRUG USE INVESTIGATION

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Inclusion Criteria:

• patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

Exclusion Criteria:

• Patients with past history of hypersensitivity to any of the ingredients of XALKORI